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Making Cancer History
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Therapeutic Window
New drug formulation allows
researchers to predict the
optimal dose.

5

House Call
Moderate exercise /
offers many benefits
for patients with cancer.
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Infection Control

A comprehensive approach

is needed to lower infection
rates in patients.

REPORT TO PHYSICIANS

New Agents
and Strategies
Help Oncologists
Balance Benefits
and Risks of
Chemotherapy

While receivin chemvrheri

the Amni.11nm""'
Center,

in

visits wi

Hwang. an assistant

professor in the Department
of General Internal Medicine,
Ambulatory Treannent,
and Emergency Care.

by Sunni Hosemann

ince the accidental discovery
that mustard gas, an agent
developed for chemical
warfare, could be used
to treat certain types of cancer,
oncologi,sts have taken on the uneasy
responsibility of meting out powerful
drugs to their patients .

Every day, clinical oncologists weigh the
risks and benefits of different types of chemo
therapy and counsel their patients about the
treatment decisions they face. Meanwhile,
cancer investigators continue their search for
kinder, gentler cures.
Chemotherapy regimens are associated with
complications and adverse effects that can
increase morbidity and mortality races, lower
quality of life, and raise the economic costs
associated with cancer care. Some adverse
(Continued on next page)
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Balancing the Benefits and Risks of Chemotherapy
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the subject of ongoing research.
Some newer classes of drugs, while
not without adverse effects, are more
benign in that regard because they
are more targeted to tumor cells. For
example, the drug imatinib (STI571),
used to treat patients with chronic
myelogenous leukemia, targets a specific
gene in tumor cells and does not act
on other cells, thus causing fewer
adverse effects than standard chemo
therapy.
Often, an advance may be in the
form of a new combination of drugs.
The use of the chemotherapy combina
tion ABVD (doxorubicin, bleomycin,
vinblastine, and dacarbazine) in the
treatment of Hodgkin's disease is an
example. Depending on the stage of
disease, ABVD-used instead of or
alternating with the previous longtime
standard combination regimen MOPP
( mechlorethamine, vincristine, pro
carbazine, and prednisone)-has
been shown to result in fewer cases
of treatment-induced sterility and

secondary leukemia , while demonstrat
ing the same or improved efficacy.

Hematological support

Damage co blood cells is a common
and worrisome complication of cyto
toxic chemotherapy, causing anemia
and neutropenia that can interrupt or,
in some cases, force the cessation of
potentially curative treatment. According
co Robert S. Benjamin, M.0., professor
and chairman of the Department of
Sarcoma Medical Oncology at M. 0.
Anderson, the development of colony
stimulating factors such as granulocyte
macrophage colony-stimulating factor
(GM-CSF) and G-CSF was an impor
tant advance. These agents are widely
used to speed up neucrophil recovery.
The use of G-CSF to help support white
blood cells, for example, has made it
possible to continue giving therapeutic
doses of chemotherapy, avoid reducing
the dosage, or in some cases, give
higher and more effective doses.
"Certainly, having approaches to
support patients through the
myelosuppressive phase of their
therapy has had an impact in
many cancers, but it has been
critical for the treatment of
sarcoma, where it is necessary
to use relatively high doses
of chemotherapy," said Dr.
Benjamin.
Whereas G-CSF and GM
CSF have been used successfully
to reduce the incidence of
neucropenia and the risk of
infections in patients receiving
cytotoxic creacmencs, chrombo
cytopenia has been managed
primarily with platelet transfu
sions and chemotherapy dose
reductions, according co S aroj
Vadhan-Raj, M.D., professor
of medicine and chief of M . D.
Anderson's Section of Cytokines
and Targeted Therapies in the
Department of Bioimmuno
thcrapy.
Dr. Vadhan is working with
recombinant human thrombo
poietin (rhTPO) to ameliorate
Dr. Laura L. Michaud, a clinical pharmacy
thrornbocytopenia associated
specialist in the Division of Pharmacy, meets
with intensive chemotherapy
with patient
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The search continues
for ways to make
chemotherapy more
tolerable, but years
of hard work and
research in countless
laboratories and
clinics are tipping the
scales in favor of
patients.
in patients with gynecologic malignan
cies or high-risk sarcoma. In early
clinical trials at M. D. Anderson and
elsewhere, thrombopoietin has shown
very potent platelet-stimulating activity
in patients with cancer.
"Despite the promising results and
excellent safety profile, however, the
clinical development of this platelet
growth factor has been very slow, in
part because rhTPO has a delayed peak
response and is not consistently effec
tive when given after chemotherapy,"
Dr. Vadhan said. "We have now shown,
in a recent trial in patients with sar
coma receiving intensive chemotherapy,
that only two doses of rhTPO-one
dose given a few days before chemo
therapy and one dose given after
chemotherapy-were effective in
abrogating severe thrombocytopenia."
Randomized, double-blind clinical
trials are ongoing to determine the
safety and efficacy of this agent in
patients at high risk for severe
thrombocytopenia.
The search continues for ways to
make chemotherapy more tolerable,
but years of hard work and research in
countless laboratories and clinics are
tipping the scales in favor of patients.•
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